Danaher Corporation

Danaher Corporation

DHRNYSE / NASDAQHealthcareLarge cap

$220.36-$7.20 (-3.2%)

Last close · Data as of Nov 20, 2026

Market cap
$132.1B
P/E
36.6x
EV / EBITDA
21.2x
Revenue
$24.6B
Net margin
14.7%
ROCE
6.1%

-0.8% over the last year

Danaher Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.7%
3M
+2.1%
6M
+28.8%
1Y
-0.8%
5Y
-20.9%

52-week range

Day change -$7.20 (-3.2%) from $228 to $220 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in DHR, bought on each weekday since 2021.

News & filings

What Danaher filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity of 6.9% against a peer median of 13.5%.

Strengths (1)

  • Operating profit was 17.0 times interest costs.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments.

Read moreShow less

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Sector
Healthcare
Shares outstanding
712.8M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$132.1B
P/E
36.6x
P/B
2.5x
EV / EBITDA
21.2x
EV / Sales
6.0x
P/S
5.4x
52-week high
$242.05
52-week low
$161.91

Profitability

Operating margin
19.1%
Net margin
14.7%
EBITDA margin
28.3%
ROE
6.9%
ROCE
6.1%
ROA
4.3%
Asset turnover
0.29

Growth

Revenue
$24.6B
Revenue growth, 1Y
2.9%
Revenue CAGR, 3Y
-2.7%
Net profit growth, 1Y
-7.3%
Free cash flow
$5.3B

Solvency

Current ratio
1.87
Debt / Equity
0.37
Debt / Assets
0.24
CFO / Net profit
1.78
Cash / Market cap
3.5%

Where the revenue went

Of every $100 of FY2025 revenue, $15 was left as net income.

Danaher Corporation income statement flow, FY2025
Danaher Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$10.0B
RevenueGross profit$14.5B
Gross profitResearch and development$1.6B
Gross profitSelling, general and administrative$8.2B
Gross profitOperating income$4.7B
Operating incomePretax income$4.2B
Operating incomeInterest and other expense$457.0M
Pretax incomeTax and other$619.0M
Pretax incomeNet income$3.6B

Revenue and net profit

Revenue grew 2.9% in FY2025; net profit is the dashed line.

Danaher Corporation revenue and net profit by fiscal year
Danaher Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$26.6B$7.2B
FY2023$23.9B$4.8B
FY2024$23.9B$3.9B
FY2025$24.6B$3.6B

Cash flows

FY2025: $6.4B from operations, $5.3B free after investment (dashed).

Danaher Corporation operating and free cash flow by fiscal year
Danaher Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$8.5B$7.4B
FY2023$7.2B$5.8B
FY2024$6.7B$5.3B
FY2025$6.4B$5.3B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$24.6B+2.9%1Y
EBITDA
$6.9B-4.5%1Y
Net profit
$3.6B-7.3%1Y
Cash from operations
$6.4B-4.1%1Y
Free cash flow
$5.3B-0.7%1Y
Revenue CAGR, 3Y
-2.7%
Net profit CAGR, 3Y
-20.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$24.6B$6.9B$3.6B$5.3B6.9%+2.9%-7.3%

Monthly returns

Month-by-month returns of DHR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$83.5B
Liabilities$30.9B
Equity$52.5B
Paid-in capital$17.2B
Retained earnings$46.9B
Treasury stock$11.4B
Minority interest$7.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; DHR highlighted.

P/E against peers

DHR trades at 36.6x earnings against a peer median of 26.3x (a 39% premium).

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Danaher CorporationDHRthis companyP/E ↑ premium$132.1B36.6x2.5x6.9%21.2x
Abbott LaboratoriesABT$158.1B24.2x3.0x12.5%13.5x
Intuitive Surgical, Inc.ISRG$148.3B51.9x8.3x16.0%39.3x
Pfizer Inc.PFE$146.4B18.8x1.7x9.0%12.5x
CVS Health CorporationCVS$121.0B68.4x1.6x2.4%19.5x
Bristol-Myers Squibb CompanyBMY$115.6B16.4x6.3x38.2%10.0x
Stryker CorporationSYK$115.5B35.6x5.2x14.5%20.2x
Vertex Pharmaceuticals IncorporatedVRTX$112.1B28.4x6.0x21.2%22.4x
Medtronic plcMDT$105.2B22.6x2.2x9.7%14.3x
Peer median—26.3x4.1x13.5%16.9x

Year-to-date ROI

DHR since 1 January, against earlier years.

Historical volatility

DHR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Danaher Corporation operating margin by fiscal year
Danaher Corporation operating margin by fiscal year
DateOperating margin
FY202228.3%
FY202321.8%
FY202420.4%
FY202519.1%
LineFY2025
Cost of revenueCost Of Revenue$10.0B
Gross profitGross Profit$14.5B
Operating expensesOperating Expense$9.8B
Research and developmentResearch And Development$1.6B
Selling, general and administrativeSelling General And Administration$8.2B
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$19.9B
Pretax incomePretax Income$4.2B

Learn while you research

Academy chapters picked for Danaher Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 36.6, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →